Last updated on March 2019

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Brief description of study

Prospective randomized open multicenter trial with blinded adjudication of endpoints to assess the efficacy of six-month low-dose LMWH (Low Molecular Weight Heparin) for the prevention of symptomatic or incidental VTE in patients with stage IV lung cancer and elevated D-dimer.

Detailed Study Description

Adult patients aged 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place in outpatient clinic at day 90, day 180 and day 360. Blood sampling for biomarkers will be performed at inclusion visit and day 90.

Clinical Study Identifier: NCT03090880

Find a site near you

Start Over

Centre Oscar Lambret

Lille, France
  Connect »